The evaluation of efficacy and tolerability of regorafenib treatment in metastatic colorectal cancer: Single center experience [Metastatik kolorektal kanserde regorafenib kullaniminin etkinlik ve Yan Etki Açisindan Değerlendirilmesi: Tek merkez deneyimi]
| Autor: | Çakar B., Sürmeli Z., Gürsoy P., Güney S.C., Fetullaoglu Z., Polater S., Karabulut B. |
|---|---|
| Jazyk: | turečtina |
| Rok vydání: | 2019 |
| Předmět: | |
| Popis: | 2-s2.0-85073722355 Objective: Regorafenib is an oral multitarget kinase inhibitor that has single agent activity on metastatic colorectal cancer (mCRC). The main issue in regorafenib use is the higher frequency of adverse events and intolerance due to treatment. In this study, we aimed to evaluate our patients’ regorafenib use and drug tolerance. Materials and Methods: Medical records of mCRC patients who admitted to Ege University Medical Oncology unit between 2010-2017 were retrospectively reviewed. In patients who received regorafenib; the treatment initial dose, adverse events during treatment, dose reduction and survival analyses were recorded. Results: We identified 38 patients who had received regorafenib treatment. The median age was 56 (30-76). Forty-seven percent of the patients had started treatment with reduced dose. Patients who had dose reduction in the beginning of treatment or in follow-up period showed similar progression free survival (PFS) and overall survival (OS) when compared to patients who received standart dose (low dose: med PFS: 4.1 months, med OS 6.6 months; standart dose group med PFS: 4.0 months, med OS: 5.9 months). The regorafenib treatment ceased in 16% of the patient group due to treatment intolerance. When the study group was analysed according to subgroups defining the primary tumor localization, excision of primary lesion, the PFS interval in prior treatment setting, metastatic site number and line of regorafenib use; neither subgroup was found to be associated with better response to regorafenib. Conclusion: The survival results were similar in patients who had standart treatment dose or who had dose reduction in initiation of treatment or folllow-up period. © 2019 by Türkiye Klinikleri. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|